Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study

BACKGROUND AND PURPOSE: SARS‐CoV2 vaccination is recommended for patients with multiple sclerosis (pwMS), but response may be limited by disease‐modifying‐treatments (DMTs). The aim of this study was to compare the rates of humoral immune response and safety of SARS‐CoV‐2 vaccines in pwMS and health...

Descripción completa

Detalles Bibliográficos
Autores principales: Bsteh, Gabriel, Hegen, Harald, Traxler, Gerhard, Krajnc, Nik, Leutmezer, Fritz, Di Pauli, Franziska, Kornek, Barbara, Rommer, Paulus, Zulehner, Gudrun, Dürauer, Sophie, Bauer, Angelika, Kratzwald, Sarah, Klotz, Sigrid, Winklehner, Michael, Deisenhammer, Florian, Guger, Michael, Höftberger, Romana, Berger, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305190/
https://www.ncbi.nlm.nih.gov/pubmed/35102646
http://dx.doi.org/10.1111/ene.15265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305190/
https://www.ncbi.nlm.nih.gov/pubmed/35102646
http://dx.doi.org/10.1111/ene.15265

Ejemplares similares